Drug Profile
Research programme: SVP platform-based gene therapeutics - Spark Therapeutics
Alternative Names: SVP platform-based factor VIII gene therapy - Spark Therapeutics; SVP platform-based FVIII gene therapy - Spark Therapeutics; SVP-Rapamycin plus FVIII gene therapy - Spark TherapeuticsLatest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Spark Therapeutics
- Developer Cartesian Therapeutics; Spark Therapeutics
- Class Blood coagulation factors; Gene therapies
- Mechanism of Action Blood coagulation factor replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia A